Glypican-1 as a novel immunotherapeutic target in prostate cancer.

Zaslavsky, A; Adams, M; Wissmueller, S; Campbell, D; Klingemann, H; Walsh, B; Palapattu, GS

JOURNAL OF CLINICAL ONCOLOGY, 2018; 36 (6):